Ikena Oncology, Inc. (NASDAQ:IKNA) Short Interest Update

Ikena Oncology, Inc. (NASDAQ:IKNA) was the recipient of a large growth in short interest in February. As of February 15th, there was short interest totalling 154,100 shares, a growth of 34.1% from the January 31st total of 114,900 shares. Currently, 1.1% of the shares of the stock are short sold. Based on an average daily volume of 226,700 shares, the short-interest ratio is currently 0.7 days.

Analysts Set New Price Targets

IKNA has been the subject of a number of recent analyst reports. HC Wainwright restated a “buy” rating and set a $4.00 price target on shares of Ikena Oncology in a research report on Monday, November 11th. Wedbush restated a “neutral” rating and set a $2.00 price target on shares of Ikena Oncology in a research report on Monday, December 23rd.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BML Capital Management LLC grew its position in Ikena Oncology by 395.8% in the fourth quarter. BML Capital Management LLC now owns 3,585,866 shares of the company’s stock worth $5,881,000 after acquiring an additional 2,862,578 shares in the last quarter. Gilead Sciences Inc. purchased a new position in Ikena Oncology in the fourth quarter worth $3,294,000. NEA Management Company LLC grew its position in Ikena Oncology by 5.3% in the third quarter. NEA Management Company LLC now owns 600,063 shares of the company’s stock worth $1,038,000 after acquiring an additional 30,013 shares in the last quarter. Peapod Lane Capital LLC purchased a new position in Ikena Oncology in the fourth quarter worth $833,000. Finally, Geode Capital Management LLC grew its position in Ikena Oncology by 21.0% in the fourth quarter. Geode Capital Management LLC now owns 327,962 shares of the company’s stock worth $538,000 after acquiring an additional 56,936 shares in the last quarter. 75.00% of the stock is currently owned by hedge funds and other institutional investors.

Ikena Oncology Stock Performance

Shares of NASDAQ:IKNA opened at $1.35 on Thursday. Ikena Oncology has a 52-week low of $1.22 and a 52-week high of $1.94. The firm has a fifty day moving average of $1.49 and a 200 day moving average of $1.62. The firm has a market capitalization of $65.15 million, a PE ratio of -1.10 and a beta of 0.48.

Ikena Oncology Company Profile

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.